Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma

Radiology

Volumn 266, Issue 1, 2013, Pages 130-140

  Jamin, Yann ^a   Tucker, Elizabeth R ^a   Poon, Evon ^a   Popov, Sergey ^a   Vaughan, Lynsey ^a   Boult, Jessica K R ^a   Webber, Hannah ^a   Hallsworth, Albert ^a   Baker, Lauren C J ^a   Jones, Chris ^a   Koh, Dow Mu ^a   Pearson, Andrew D J ^a   Chesler, Louis ^a   Robinson, Simon P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CEDIRANIB; CYCLOPHOSPHAMIDE; GADOLINIUM PENTETATE MEGLUMINE; N ACETYLCOLCHINOL PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG RESPONSE; MOUSE; MYCN GENE; NEUROBLASTOMA; NEUROIMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84871680157     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12120128     Document Type: Article

References (40)

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362(23):2202-2211.
2. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14(2):405-414. (Pubitemid 26051001)
3. Balis FM. Clinical trials in childhood cancers. Oncologist 2000;5(3):xii-xiii. (Pubitemid 30429936)
4. Moreno L, Chesler L, Hargrave D, Eccles SA, Pearson ADJ. Preclinical drug development for childhood cancer. Expert Opin Drug Discov 2011;6(1):49-64.
5. O'Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 2008;9(8):766-776. (Pubitemid 352038315)
6. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16(11):2985-2995. (Pubitemid 27234938)
7. Chesler L, Goldenberg DD, Collins R, et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 2008;10(11):1268-1274.
8. Hogarty MD, Norris MD, Davis K, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008;68(23):9735-9745.
9. Chesler L, Schlieve C, Goldenberg DD, et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 2006;66(16):8139-8146. (Pubitemid 44299181)
10. Chesler L, Weiss WA. Genetically engineered murine models - contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin Cancer Biol 2011;21(4):245-255.
11. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102(11):1555-1577.
12. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8(6):1974-1983. (Pubitemid 34633761)
13. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62(24):7247-7253. (Pubitemid 36025246)
14. Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010;28(35):5174-5181.
15. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50(3):581-587. (Pubitemid 351155829)
16. Morton CL, Maris JM, Keir ST, et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;58(4):566-571.
17. Walker-Samuel S, Orton M, McPhail LD, et al. Bayesian estimation of changes in transverse relaxation rates. Magn Reson Med 2010;64(3):914-921.
18. Boult JKR, Walker-Samuel S, Jamin Y, Leiper JM, Whitley GS, Robinson SP. Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. J Pathol 2011;225(3):344-352.
19. D'Agostino RB. Tests for normal distribution. In: D'Agostino RB, Stepenes MA, eds. Goodness-of-fit techniques. New York, NY: Marcel Dekker, 1986; 367-413.
20. Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 2006;7:123.
21. Goo HW. Whole-body MRI of neuroblastoma. Eur J Radiol 2010;75(3):306-314.
22. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261(1):243-257.
23. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5(6):423-435. (Pubitemid 40791485)
24. Morton CL, Favours EG, Mercer KS, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 2007;25(4):285-295. (Pubitemid 46944850)
25. Meany HJ, Sackett DL, Maris JM, et al. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. Pediatr Blood Cancer 2010;54(1):47-54.
26. Robinson SP, McIntyre DJ, Checkley D, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003;88(10):1592-1597. (Pubitemid 36713788)
27. Bradley DP, Tessier JJ, Lacey T, et al. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging 2009;27(3):377-384.
28. McSheehy PM, Weidensteiner C, Cannet C, et al. Quantified tumor T1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability. Clin Cancer Res 2010;16(1):212-225.
29. O'Connor JP, Carano RA, Clamp AR, et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15(21):6674-6682.
30. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95. (Pubitemid 46075199)
31. Braunschweiger PG, Schiffer LM, Furmanski P. 1H-NMR relaxation times and water compartmentalization in experimental tumor models. Magn Reson Imaging 1986;4(4):335-342. (Pubitemid 17172214)
32. Robinson SP, Kalber TL, Howe FA, et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 2005;7(5):466-474. (Pubitemid 40791866)
33. Burrell JS, Walker-Samuel S, Baker LC, et al. Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. Int J Cancer 2012;131(8)1854-1862.
34. Nathan P, Zweifel M, Padhani AR, et al. Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. Clin Cancer Res 2012;18(12):3428-3439.
35. Waterton JC, Pylkkanen L. Qualification of imaging biomarkers for oncology drug development. Eur J Cancer 2012;48(4):409-415.
36. Bradley DP, Tessier JJ, Ashton SE, et al. Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. Neoplasia 2007;9(5):382-391. (Pubitemid 46799981)
37. Jackson A, O'Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13(12):3449-3459. (Pubitemid 46955104)
38. McPhail LD, McIntyre DJ, Ludwig C, et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 2006;8(3):199-206. (Pubitemid 43671235)
39. Sinkus R, Van Beers BE, Vilgrain V, DeSouza N, Waterton JC. Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. Eur J Cancer 2012;48(4):425-431.
40. Humphries PD, Sebire NJ, Siegel MJ, Olsen OE. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 2007;245(3):848-854. (Pubitemid 350127356)